Vir Biotechnology, Inc. · NASDAQ:VIR
Vir Biotechnology — Corporate Update (February 2022)
20 slides from Vir Biotechnology's corporate update, Feb 24, 2022
Slide 1: A World Without Infectious Disease: Corporate Overview
Exhibit 99.2 A World Without Infectious Disease C o r p o r a t e O v e r v i e w F e b r u a r y 2 4 , 2 0 2 2 V I R B I O T E C H N O L O G Y , I N C . WHO: World Health Organization; HBV: Hepatitis B Virus; HIV: Human Immunodeficiency Virus
Slide 2: Legal Disclaimer: Forward-Looking Statements
L E G A L D I S C L A I M E R Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near- term financial performance (including near-t
Slide 3: 2021: Proving Our Mettle
2 0 2 1 : P R O V I N G O U R M E T T L E Delivered sotrovimab to patients around the world >750,000 doses sold, ~90% delivered, $917.2 million of sotrovimab collaboration revenue recognized IM trial achieved primary endpoint Stood up to Omicron and other tested variants Extended leadership in HBV f
Slide 4: A pivotal moment for VIR
$ 917.2 million sotrovimab collaboration 1 revenues in 2021, more expected in 2022. Strong balance sheet. Resources to help save even more lives, build more value Pursuing a robust and diverse pipeline 2 in large infectious diseases: COVID-19, A pivotal Hepatitis B, Influenza and HIV, with multiple
Slide 5: Clinical Development Pipeline
C L I N I C A L D E V E L O P M E N T P I P E L I N E Antibody siRNA T cell Disease Area Product Candidate Treatment / Prophylaxis Preclinical Phase 1 Phase 2 Phase 3 Authorized Collaborator † Sotrovimab Treatment (Early-IV) COVID-19 mAb GlaxoSmithKline † Sotrovimab Treatment (Early-IM) GlaxoSmithKl
Slide 6: COVID-19: Aspiring to Make COVID History
COVID-19 A S P I R I N G T O M A K E C O V I D H I S T O R Y © 2022 Vir Biotechnology, Inc. 06
Slide 7: Sotrovimab: COVID-19 unmet needs
S O T R O V I M A B COVID-19 unmet needs ~429M ~6M Cases to date globally Deaths to date globally https://coronavirus.jhu.edu/map.htm © 2022 Vir Biotechnology, Inc. 07 As of February 23, 2022
Slide 8: Sotrovimab: Reaching patients around the world
S O T R O V I M A B Reaching patients Working to enable broader patient access by: around the world Sotrovimab currently has marketing approval, Increasing 1H2022 supply to 2 million temporary authorization or emergency use 1 doses, additional doses in 2H2022 authorization in >40 countries ~1.7 mill
Slide 9: What's Next? Preparing for the next wave and future pandemics
W H A T ’ S N E X T ? Preparing for the next wave and for future pandemics SMALL MOLECULE THAT ANTIBODIES THAT ARE PAN-CORONAVIRUS TREATS MULTIPLE EVEN BROADER AND VACCINE DESIGNED TO RESPIRATORY DISEASES: MORE POTENT THAN BE VARIANT PROOF COVID, FLU, ETC SOTROVIMAB Manufacturing initiated Initial p
Slide 10: Hepatitis B: In Pursuit of a Functional Cure
Hepatitis B I N P U R S U I T O F A F U N C T I O N A L C U R E © 2022 Vir Biotechnology, Inc. 10
Slide 11: Hepatitis B: Unmet Needs and Vir's Answer
H E P A T I T I S B UNMET NEEDS VIR’S ANSWER In pursuit of a functional We are developing multiple combination therapies ~300M cure intended to both suppress Approximately 300 million people in the world live with chronic Hepatitis B the virus (“remove the brake”) and stimulate the immune system (“s
Slide 12: Hepatitis B: Broad portfolio in pursuit of a functional cure
H E P A T I T I S B Broad portfolio in pursuit of a functional cure VIR-2218 PHASE 2 DATA ONGOING PHASE 2 COMBINATION TRIALS WITH VIR-2218 Potential Best-In-Class siRNA as “backbone” of therapy VIR-3434 mAb 1 2 PEG-IFN-⍺ GS-9688 TLR-8 agonist 3 Nivolumab PD-1 antagonist Placebo 20 mg 50 mg 100 mg 20
Slide 13: MARCH Trial: Evaluating functional cure potential from combinations
M A R C H T R I A L Evaluating functional cure potential from combinations Part B*: additional cohorts to determine dose, length of treatment, and evaluate Part A: short treatment courses designed to rapidly evaluate safety, PK, and HBsAg suppression, when VIR-3434 is given weekly triple cocktails,
Slide 14: Influenza, HIV and Innovation: Moving the Fight Forward
Influenza, HIV and Innovation M O V I N G T H E F I G H T F O R W A R D © 2022 Vir Biotechnology, Inc. 14
Slide 15: Influenza: Unmet Need and Vir's Answer
I N F L U E N Z A UNMET NEED VIR’S ANSWER Working to Antibodies intended to provide overcome the meaningfully higher levels of protection for ~500K the most vulnerable: e.g., the elderly with COPD or CHF limitations Deaths from influenza globally each year V I R - 2482: of current • Covers all major
Slide 16: HIV: Unmet Need and Vir's Answer
H I V UNMET NEED VIR’S ANSWER On a mission P R E V E N T I O N : to prevent HCMV-based vaccine intended to “program” ~1.5M unique T cell responses against HIV New cases per year and cure* V I R -1111 High unmet need for a vaccine for • Currently in phase 1 the billions of individuals who are or • No
Slide 17: Innovation: Deploying our technologies to create enduring medicines
I N N O V A T I O N Deploying our technologies to create enduring medicines C U R R E N T T E C H N O L O G Y P L A T F O R M S Broadly-neutralizing antibodies that can treat today’s and tomorrow’s variants A N T I B O D I E S T C E L L T cell immunomodulators for the prevention and cure of chronic
Slide 18: Catalysts: Looking Ahead To
Catalysts L O O K I N G A H E A D T O 2 0 2 2 © 2022 Vir Biotechnology, Inc. 18
Slide 19: Anticipated Catalysts
2 0 2 2 A N T I C I P A T E D C A T A L Y S T S COVID-19 HBV INFLUENZA HIV F I R S T H A L F S E C O N D H A L F Sotrovimab (mAb) VIR-7832 (mAb) F i l e D a t a BLA (Early Treatment, IV, IM) Phase 1b add’l clinical data (Early Treatment, AGILE) VIR-2218 (siRNA) + VIR-3434 (mAb) Sotrovimab (mAb) D a
Slide 20: Fourth quarter and FY financial overview
F o u r t h q u a r t e r a n d F Y 2 0 2 1 f i n a n c i a l o v e r v i e w E P S T O T A L R E V E N U E 4Q2021: $812.7M 4Q2021: FY2021: $1.1B $4.01 per share, basic $3.92 per share, diluted FY2021: S O T R O V I M A B $4.07 per share, basic C O L L A B O R A T I O N R E V E N U E $3.96 per share